Solventum Corporation
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsSolventum is a global healthcare company spun off from 3M that sells wound care, dental, and health information software products across three reportable segments.
What they do
Solventum develops, manufactures, and commercializes medical, dental, and health information products, leveraging material science, data science, and digital capabilities. It serves hospitals, clinics, and dental practices with products spanning prevention, diagnosis, treatment, and recovery. The company operates as a standalone public company following its spin-off from 3M.
Revenue drivers
- MedSurg — Provides negative pressure wound therapy, advanced wound dressings, skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes, stethoscopes, electrodes, and medical OEM technologies. It represented 57.9% of 2025 total sales.
- Dental Solutions — Offers dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents across preventative, restorative, and orthodontic needs. It accounted for 16.2% of 2025 total sales.
- Health Information Systems — Supplies software such as computer-assisted physician documentation, coding automation, classification methodologies, speech recognition, and data visualization platforms. It represented 16.3% of 2025 total sales.
Recent performance
Second quarter 2026 net sales were $2.209 billion, up 2.2% on a reported basis and 9.5% on an organic basis. GAAP diluted EPS was $0.53, while adjusted diluted EPS was $2.55, a 50.9% increase. Operating cash flow was $227 million and free cash flow was $144 million. Net income was $92 million and adjusted operating income margin was 28.4%. Sales growth benefited from approximately $125 million of advanced customer orders ahead of a July 2026 ERP deployment.
Strategy
Solventum is pursuing portfolio optimization, including the announced intent to separate its Health Information Systems business as a dedicated MedTech company. It sold its Purification and Filtration business to Thermo Fisher Scientific for approximately $4 billion in 2025 and acquired Acera Surgical. The company invests in R&D within each segment and cross-segment shared technologies. Management aims to strengthen focus, accelerate innovation, and enhance growth opportunities.
Risks
- Spin-off transition — Historical financial information prior to the spin-off may not be representative and the company faces risks as a standalone entity, including loss of 3M's brand benefits.
- Separation execution — The intended separation of the Health Information Systems business may not be completed on favorable terms or may cause disruption to operations and customer relationships.
- Tariff and trade policy — Tariffs imposed under various U.S. authorities, including Sections 122, 301, 338, and 232, could affect costs, though IEEPA tariff refunds of approximately $120 million were recognized in June 2026.
- ERP deployment disruption — The July 2026 U.S. enterprise resource planning deployment benefited second quarter sales by approximately $125 million through advanced orders, but may cause near-term volatility in sales and operations.
Outlook
Management increased full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow. The company expects to continue its transformation and portfolio optimization, including evaluating separation pathways for the Health Information Systems business. It remains on track to achieve long-term objectives as a more focused MedTech company.